Abstract:Epilepsy-associated brain tumors (EATs) are usually slow-growing, with seizures as the primary and most dominant symptom. BRAF (v-raf murine sarcoma viral oncogene homolog B1) gene mutations have been found in several subsets of EATs; the V600E mutation is currently believed to contribute to the intrinsic epileptogenicity and tumor growth. However, the relationship between BRAF V600E gene mutation and clinical characteristics in EAT patients is not clear. In this study, we aimed to systematically review the frequency of BRAF V600E gene mutation, as well as the relationship between BRAF V600E gene mutation and clinical characteristics, which may help with the diagnosis and treatment of EATs. Cochrane Library, PubMed, Embase, CNKI, WanFang Data, CQVIP, and SinoMed databases were searched up to October 2020 to identify peer-reviewed human studies on assessing the relationship between BRAF V600E gene mutations and clinical characteristics in EATs. The following data were calculated: the frequency of BRAF V600E mutation and clinical feature comparison between BRAF V600E mutations and wild type in EATs, such as gender, age of seizure onset, duration of epilepsy, location of tumors, and Engel outcome. A total of 12 articles were included in the analysis. Five hundred and nine patients with epilepsy-associated brain tumors were screened for the BRAF V600E gene mutation. Among them, 193 patients had the BRAF V600E mutation (34.06%, 95% CI = 0.25 to 0.43). The subgroup analyses of BRAF V600E mutation showed positive frequency of 44.76% (95% CI = 0.36 to 0.54) in ganglioglioma, 24.75% (95% CI = 0.14 to 0.37) in gysembryoplastic neuroepithelial tumor, 2.15% (95% CI = 0 to 0.19) in angiocentric glioma, and 50.16% (95% CI = 0.33 to 0.68) in pleomorphic xanthoastrocytoma. Compared with the overall frequency, the BRAF V600E positive frequency in ganglioglioma was significantly higher ( P = 0.0283). We also found that BRAF V600E gene mutation was significantly associated with age at seizure onset (MD = −2.37; 95% CI = −4.33 to −0.41; P = 0.02). There was no statistical difference between BRAF V600E mutations and wild type in gender, duration of epilepsy, tumor site, and Engel outcome comparison. In conclusion, our updated and comprehensive meta-analysis based on a large number of clinical data demonstrated that BRAF V600E mutation is a specific biomarker and could be a pharmacological target for ganglioglioma patients and an exclusion diagnostic criterion for angiocentric glioma. This meta-analysis suggested the critical role of BRAF V600E mutation in the occurrence and development of EATs. Our findings help to elucidate the progression mechanisms in EATs and develop future therapeutic strategies for EATs.

Transcriptional features of low‐grade neuroepithelial tumors with the BRAF V600E mutation associated with epileptogenicity

Mapping The Spatio-Temporal Pattern Of The Mammalian Target Of Rapamycin (Mtor) Activation In Temporal Lobe Epilepsy

Epilepsy Surgery for Low-Grade Epilepsy-Associated Neuroepithelial Tumor of Temporal Lobe: a Single-Institution Experience of 61 Patients

RNA Sequencing Analysis of Cortex and Hippocampus in a Kainic Acid Rat Model of Temporal Lobe Epilepsy to Identify Mechanisms and Therapeutic Targets Related to Inflammation, Immunity and Cognition.

Clinical Characteristics of BRAF V600E Gene Mutation in Patients of Epilepsy-Associated Brain Tumor: a Meta-analysis

Low-grade epilepsy-associated neuroepithelial tumors: Tumor spectrum and diagnosis based on genetic alterations

Clinical characteristics and surgical outcomes of low-grade epilepsy-associated brain tumors

Mesial temporal lobe epilepsy and hippocampal sclerosis associated with BRAFV600E mutant neurons in the Cornu Ammonis: an uncertain pathogenesis and a diagnostic challenge

BRAF V600E Mutation in Epilepsy-Associated Glioneuronal Tumors: Prevalence and Correlation with Clinical Features in a Chinese Population

Long-term epilepsy associated-tumors (LEATs): what is new?

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients with the BRAF-V600E Mutation

Integrated Proteomics and Protein Co-expression Network Analysis Identifies Novel Epileptogenic Mechanism in Mesial Temporal Lobe Epilepsy

High-resolution Transcriptomics Informs Glial Pathology in Human Temporal Lobe Epilepsy

Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.

BRAFV600E expression in neural progenitors results in a hyperexcitable phenotype in neocortical pyramidal neurons

Bioinformatic Analysis Identifies Key Transcriptome Signatures in Temporal Lobe Epilepsy

Changes in the Dentate Gyrus Gene Expression Profile Induced by Levetiracetam Treatment in Rats with Mesial Temporal Lobe Epilepsy

Low‐grade epilepsy‐associated tumors: Epilepsy outcome and antiseizure medication discontinuation after lesionectomies as first‐line surgical approach in pediatric population

Surgical treatment of long-term epilepsy-associated tumors guided by stereoelectroencephalography

Differential gene expression underlying epileptogenicity in patients with gliomas

Emerging roles of long non‐coding RNAs in human epilepsy